Literature DB >> 32209897

Short-term Outcomes of Single-port Versus Multiport Laparoscopic Surgery for Colon Cancer: The SIMPLE Multicenter Randomized Clinical Trial.

Yoon Suk Lee1, Ji Hoon Kim2, Hyung Jin Kim3, Sang Chul Lee4, Byung Mo Kang5, Chang Woo Kim6, Sang Woo Lim7, Suk-Hwan Lee6, Jun Gi Kim1.   

Abstract

OBJECTIVE: To compare short-term perioperative outcomes of single-port laparoscopic surgery (SPLS) and multiport laparoscopic surgery (MPLS) for colon cancer. SUMMARY BACKGROUND DATA: Although many studies reported short- and long-term outcomes of SPLS for colon cancer compared with MPLS, few have reported results of randomized controlled trials.
METHODS: This was a multicenter, prospective, randomized controlled trial with a noninferiority design. It was conducted between August 2011 and June 2017 at 7 sites in Korea. A total of 388 adults (aged 19-85 yrs) with clinical stage I, II, or III adenocarcinoma of the ascending or sigmoid colon were enrolled and randomized. The primary endpoint was 30-day postoperative complication rates. Secondary endpoints were the number of harvested lymph nodes, length of the resection margin, postoperative pain, and time to functional recovery (bowel movement and diet). Patients were followed for 30 days after surgery.
RESULTS: Among 388 patients, 359 (92.5%) completed the study (SPLS, n = 179; MPLS, n = 180). The 30-day postoperative complication rate was 10.6% in the SPLS group and 13.9% in the MPLS group (95% confidence interval, -10.05 to 3.05 percentage points; P < 0.0001). Total incision length was shorter in the SPLS group than in the MPLS group (4.6 cm vs 7.2 cm, P < 0.001), whereas the length of the specimen extraction site did not differ (4.4 cm vs 4.6 cm, P = 0.249). There were no significant differences between groups for all secondary endpoints and all other outcomes.
CONCLUSIONS: Even though there was no obvious benefit to SPLS over MPLS when performing colectomy for cancer, our data suggest that SPLS is noninferior to MPLS and can be considered an option in selected patients, when performed by experienced surgeons.Trial registration: ClinicalTrials.gov Identifier: NCT01480128.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 32209897     DOI: 10.1097/SLA.0000000000003882

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  5 in total

1.  Comparative Effectiveness of Enhanced Recovery After Surgery Program Combined With Single-Incision Laparoscopic Surgery in Colorectal Cancer Surgery: A Retrospective Analysis.

Authors:  Changgang Wang; Haoran Feng; Xiaoning Zhu; Zijia Song; You Li; Yiqing Shi; Yimei Jiang; Xianze Chen; Tao Zhang; Ren Zhao; Kun Liu
Journal:  Front Oncol       Date:  2022-01-12       Impact factor: 6.244

2.  Short-Term Outcomes of Single-Incision Laparoscopic Surgery for Colorectal Cancer: A Single-Center, Open-Label, Non-Inferiority, Randomized Clinical Trial.

Authors:  Zijia Song; Kun Liu; You Li; Yiqing Shi; Yimei Jiang; Changgang Wang; Xianze Chen; Tao Zhang; Xiaopin Ji; Ren Zhao
Journal:  Front Oncol       Date:  2021-10-25       Impact factor: 6.244

3.  Single plus one-port robotic surgery using the da Vinci Single-Site Platform versus conventional multi-port laparoscopic surgery for left-sided colon cancer.

Authors:  Sung Uk Bae; Woon Kyung Jegon; Seong Kyu Baek
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2022-01-18       Impact factor: 1.195

4.  Oncologic outcomes of single-incision laparoscopic surgery versus conventional laparoscopic surgery for colorectal cancer (CSILS): study protocol for a multicentre, prospective, open-label, noninferiority, randomized controlled trial.

Authors:  Zijia Song; Kun Liu; Tao Zhang; Bingshun Wang; Yiqing Shi; Yimei Jiang; Changgang Wang; Xianze Chen; Xiaopin Ji; Ren Zhao
Journal:  BMC Cancer       Date:  2022-07-07       Impact factor: 4.638

Review 5.  Analogies between medusa and single port surgery in gastroenterology and hepatology: A review.

Authors:  Christof Mittermair; Helmut G Weiss
Journal:  World J Gastroenterol       Date:  2021-12-21       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.